

Original article

Incidence and Potential Risk Factors for Seroconversion to Hepatitis C Positivity in Patients on Maintenance Hemodialysis in Sub-Saharan Africa

Gloria E. Ashuntantang¹, Richard Njouom², Andre-Pascal Kengne³, Antoine N. Ngemhe¹, Francois F. Kaze¹, Henry N. Luma⁴, Oudou Njoya¹.

¹ Dept. of Internal Medicine & Specialties, Faculty of Medicine & Biomedical Sciences, University of Yaoundé 1

² Virology Laboratory, Centre Pasteur du Cameroun, Yaounde

³ Medical Research Council of South Africa, Cape Town

⁴ Dept. of Microbiology, Parasitology and Hematology, Faculty of Medicine & Biomedical Sciences, University of Yaoundé 1

Corresponding author: Dr Gloria Ashuntantang: Email: maglo09@hotmail.com

Abstract

PURPOSE

Maintenance hemodialysis (HD) is a high risk milieu for nosocomial Hepatitis C virus (HCV) infection. We evaluated the rate and potential risk factors of seroconversion to anti-HCV positivity in maintenance HD patients in a tertiary hospital in Cameroon

METHODS

This was a retrospective cohort study involving 40 patients on HD for at least 3 months with a negative baseline HCV serology tested with a third -generation ELISA (*Monolisa anti-HCV plus version 2, Biorad*) who were retested by the same test during March and April 2010. Relevant clinical patient data were recorded. The Fischer and Student tests or equivalents were used to determine the rate of seroconversion to anti-HCV positivity and the potential risk factors.

RESULTS

The mean age was 48±13yrs, median duration on dialysis of 17 months (IQR12-25.7), median number of blood units transfused of 5 (IQR 3-18.5). Ten of the 40 patients developed anti-HCV antibodies on dialysis (cumulative seroconversion rate 25%). A longer duration on dialysis (14 vs. 27 months, p=0.003) and a higher number of blood units received (19.5 vs. 5 units, p<0.001) were significantly associated with seroconversion

CONCLUSION

The seroconversion rate to anti-HCV positivity in this study is alarming. Longer dialysis on duration, higher frequency of blood transfusions and perhaps non-adherence to universal infection control measures were potential risk factors of this nosocomial transmission.

KEY WORDS:

Hemodialysis, hepatitis C antibodies, seroconversion, risk factors.

Résumé

OBJECTIFS

L'hémodialyse (HD) chronique est un milieu à haut risque pour la transmission du virus de l'hépatite virale C (VHC). Nous avons évalué le taux et les facteurs de risque potentiels de séroconversion au VHC chez les hémodialysés chroniques dans un hôpital tertiaire du Cameroun.

MÉTHODES

Il s'agissait d'une étude de cohorte rétrospective incluant 40 patients en HD depuis au moins 3 mois, ayant une sérologie initiale négative au VHC par un test ELISA de troisième génération (*Monolisa anti-HCV plus version 2, Biorad*) qui étaient à nouveau testés par le même test de mars à Avril 2010. Les données cliniques importantes des patients étaient enregistrées. Les tests de Fischer et Student ou équivalents ont été utilisés pour déterminer le taux de séroconversion ainsi que les potentiels facteurs de risques.

RÉSULTATS

L'âge moyen était de 48±13ans, la durée médiane en dialyse de 17 mois (IQR12-25,7) et le nombre médian d'unités de sang transfusées de 5 (IQR 3-18,5). Dix des 40 patients ont développé des anticorps anti-VHC en dialyse (taux cumulé de séroconversion de 25%). L'ancienneté en dialyse (14 vs. 27 mois, p=0,003) et le nombre élevé d'unités de sang reçues (19,5 vs. 5 unités, p<0,001) étaient significativement associés à la séroconversion au VHC

CONCLUSION

Le taux de séroconversion au VHC dans cette étude est alarmant. Une longue durée en dialyse, la fréquence élevée des transfusions sanguines et peut-être la non-observance des mesures universelles d'hygiène étaient les facteurs de risque potentiels de cette transmission nosocomiale.

MOTS CLÉS

Hémodialyse, anticorps virus hépatite virale C, séroconversion, facteurs de risque

INTRODUCTION

Hepatitis C virus infection (HCV) is highly prevalent in patients undergoing maintenance hemodialysis where it adversely affects patient survival [1-4]. The reported prevalence of HCV varies from 1.9% to 80% in the hemodialysis population, with low rates reported in Western Europe and very high rates in Eastern Europe and Sub-Saharan Africa [5-7]. While some patients enter the dialysis program with hepatitis C positivity, the majority acquire the infection while on this therapy [8-11]. Reported seroconversion rates to HCV positivity vary from 0-42% depending on facility, country or continent [5, 6, 12-16]. Identified risk factors for seroconversion include: a long duration on dialysis, blood transfusions, a high facility prevalence of HCV, facility practices and the non-adherence to universal infection control precautions [7, 9-11, 15, 17-32]. Most of these risk factors are suggestive of a patient-to-patient transmission route through the contaminated hands of staff and objects. [11,28-30,33,34] The decline in incidence rates observed in the HD population in some countries is attributable to improved blood safety measures, the availability of erythropoietin [5-7,10,23], the implementation of universal infection control measures [18,23,35] and in some cases the isolation of anti-HCV positive patients [15,24,25,32].

Enabling factors for HCV transmission abound in the HD environment in Sub-Saharan Africa. Like other resource-limited settings, blood donor screening for HCV is inconsistent despite the high population prevalence of HCV antibodies [36, 37]. Furthermore, blood transfusion remains the main therapy for uremic anemia, [13, 31, 38, 39] while patient overcrowding in the scarce hemodialysis facilities [40] and shortage of healthcare personnel in quantity and quality [40] renders the respect of universal infection control measures elusive.

Yet very little information exists on the seroconversion to HCV positivity in patients on maintenance hemodialysis in high endemic regions of Sub-Saharan Africa.

This study was therefore designed to determine the incidence and identify potential risk factors of seroconversion to HCV positivity in patients on maintenance hemodialysis in a single center within a high endemic Sub-Saharan African country.

MATERIAL AND METHODS

This was a retrospective cohort study involving 40 patients on maintenance HD for at least 3 months with a negative baseline HCV serology tested with a third-generation ELISA at the virology laboratory of Centre Pasteur du Cameroon. The study period was March-April 2010. After an informed and written consent, relevant socio-demographic and medical data was recorded on a pre-tested questionnaire. This

included duration on dialysis and number of blood transfusions received while on dialysis. A sample of 10 ml of blood was then collected from the patients and taken to the Virology laboratory of the Centre Pasteur du Cameroon where serum was obtained. The presence of anti-HCV antibodies was checked using a commercial third-generation ELISA (Monolisa anti-HCV plus version 2, Biorad, Marnes-La-Coquette, France). The reactivity or non-reactivity of a sample was determined as previously described. [41] Briefly, a ratio (R) of Optical Densities (OD) for each sample was calculated by dividing its OD with the cut off value. A sample was scored as positive if its Ratio was equal or above 6, whereas all samples with R less than 6 were scored as negative. Ethical clearance was obtained from the Hospital ethical committee.

Statistical Analysis

Data analysis used SPSS v.17.0 (SPSS Inc., Chicago, USA) for Windows®. Results are reported as count (percentages), mean and standard deviation (SD) or median and 25th – 75th percentiles. Group comparisons used the Fisher exact test for categorical variables, and Student t test and Mann-Whitney U test for quantitative variables. A p-value < 0.05 was used to characterize statistically significant results

Study Setting

The setting is a public hemodialysis facility situated in a tertiary hospital. Created in November 2002, the center has 12 Fresenius® 4008S HD generators (Fresenius Medical Care Homburg, Germany). It serves both acute and c. The center does not practice dialyzer re-use. Patients undergo two 4-hour dialysis sessions a week, while the center runs 3-4 dialysis shifts a day. The center operates from Mondays to Saturdays, from 6a.m to 12 midnight. Chemical disinfection of HD generators is carried out between sessions in accordance with the manufacturer's protocol. There were 96 patients undergoing maintenance hemodialysis at the time of the study. The center did not practice any isolation policy for Hepatitis B and C positive patients. At the time of the study, the center had 2 nephrologists and 14 nursing staff. The nursing staff was made up of 10 state-registered nurses (SRN) and 2 assistant nurses (AS). Six of the state registered nurses were on their first job and had worked in the center for less than one year. Only three of the nurses had received at least 3 months or more of formal training in hemodialysis. Nurses worked in teams and shifts following a monthly roster. A team was usually made up of 2 SRNs and one AS. There were 2 shifts: a daytime (6a.m – 5pm), and a night-time (5p.m- midnight) one. The team usually worked 2 consecutive daytime, followed by 2 consecutive nighttime shifts, then takes off 2 days. Recombinant erythropoietin in prefilled syringes of 2000IU was available for those who could

afford but heparin in multi-dose vials was shared amongst patients. Screening of blood donors for HCV antibodies was routine practice since 1996 at the hospital blood bank. However patients could obtain blood from other blood banks in the city

RESULTS

A total of 40 patients were included in the study, with 28 (70%) being men. They had a mean age of 48 years (standard deviation 13). This mean age was

borderline higher for men than women (50.5 vs. 42.1 years, $p=0.06$), (Table 1). Participants had been on dialysis for a median duration of 17 months (25-75th percentile: 12-25.7) which was not appreciably different between men and women ($p=0.16$). During this period, they received a median number of 5 units of blood (25-75th percentiles: 3-18.5), again with no significant difference between men and women ($p=0.046$).

Table 1 - Characteristics by gender and status for conversion

Characteristic	Gender		p-value	overall	Seroconversion		p-value
	Men	Women			Positive	Negative	
N	28	12		40	10	30	
Mean age, years (SD)	50.5 (10.6)	42.1 (16.4)	0.06	48.0 (13.0)	50.0 (15.1)	47.3 (12.4)	0.58
Median duration on dialysis, months (25-75 th Percentiles)	14(10.2-22.5)	20 (14.2-27.5)	0.16	17 (12-25.7)	27 (18.5-45.5)	14 (9.7-30)	0.003
Median number of blood units received (25-75 th Percentiles)	5 (0.75-18.5)	9 (3.2-18.5)	0.46	5 (3-18.5)	19.5 (14.7-29.2)	5 (2.2-19.9)	<0.001

There was a significant positive correlation between the duration on dialysis and the number of units of blood transfusion received (Spearman correlation coefficient 0.46, $p=0.003$; Figure 1). While on dialysis, 10 patients (cumulative incidence rate 25%) seroconverted to hepatitis C positivity (Figure 2). This seroconversion rate was non-significantly higher in women than in men (42% vs. 18%, $p=0.13$, Figure 2). Compared with participants who remained seronegative for hepatitis C, those who acquired a positive status had similar age (47.3 vs. 50 years, $p=0.58$). However, they had a much longer median duration on dialysis (14 vs. 27 months, $p=0.003$); during which time they also received more units of blood (19.5 vs. 5 units, $p<0.001$, Table 1). The small number precluded further investigations through multivariable regressions analysis.




Fig. 1 Regression curve showing the correlation between duration in dialysis and the number of units of blood received





Figure 2 – Cumulative incidence of seroconversion overall and by gender

DISCUSSION

This study evaluated the incidence of seroconversion and its potential risk factors in a retrospective cohort of anti-HCV negative participants at initiation of maintenance HD in a Sub-Saharan African facility. The cumulative incidence of seroconversion was 25% within a median dialysis duration of 17 months. A long duration on dialysis and a high number of blood units received for transfusion were potential risk factors for seroconversion identified. However, only long dialysis duration was independently associated with seroconversion to HCV positivity in this study. Data on seroconversion to HCV positivity in the maintenance hemodialysis population is scarce in Sub-Saharan Africa. El Amin reported a seroconversion rate of 17.1% within a mean dialysis duration of 33.7 months in Sudan. [13] Similar high seroconversion rates have been found in recent years in the high endemic countries of North Africa, Middle East, and Asia [39, 31,42]. Khodir et al reported a seroconversion rate of 11% in 2011 in HD facilities in an Egyptian region. [42] These rates are quite high compared to the trends in most western countries during the same period where rates of less than 1% have been reported in several countries. [5,6,10,18,14] A long duration on dialysis, [5-8,10,13,17,27,32] blood transfusions, [9,20,28,31,42] a high facility prevalence of HCV, [7,19,21,24] facility practices, [5,12,22,24,30,32] and the non-adherence to universal infection control precautions. [7,11,18,21,22,29,30,31,33,35,43] have been reported as risk factors for seroconversion in several studies. The positive association between a long dialysis duration and seroconversion to HCV positivity as was seen in the present study reinforces the role played by the hemodialysis environment in this nosocomial infection. Indeed, the risk of seroconversion has been shown to increase by 10% for each year spent on HD [44]

The effect of blood transfusion could not be independently evaluated in this study due to the small numbers and the positive correlation between the number of blood units transfused and the duration on dialysis. It is obvious that those who stay longer on dialysis are more likely to receive more blood transfusions. It is worth noting however, that no case of seroconversion was observed in the 7 participants who had never received blood transfusions. Blood transfusion contrary to earlier reports no longer plays a major role in the incidence of HCV in chronically hemodialysed populations in Europe, USA, some parts of Africa and Asia. [5,6,9,10,13-15] This change in epidemiology has occurred in regions with low general population prevalence, improved blood safety and especially where access to recombinant erythropoietin has rendered blood transfusions obsolete in treating uremic anemia. In this study, the

mean number of blood units received per participant was 12, within a median dialysis duration of 17 months, compared to a mean of 1.3 units reported in Belgium over a similar dialysis duration [18]. The post-transfusional risk of infection has been reported as being very low in western countries. [45] Blood transfusion however continues to be a major risk factor for HD acquired HCV infection in regions with high general population prevalence such as Egypt and Pakistan. [31, 39,42] Khodir found blood transfusion to be significantly associated with HCV seroconversion in 2011 among patients undergoing long-term HD in a region in Egypt [42]. It is therefore plausible that blood transfusions will continue to play an important role in regions with high population prevalence, inconsistent blood screening for HCV, and where blood transfusion remains the main therapy for uremic anemia.

The high population prevalence of HCV [36], coupled with inconsistent blood donor screening for HCV antibodies in the recent past [37] reported in Cameroon, makes blood transfusion a possible risk factor in this study

Other factors not addressed in this study such as facility prevalence and the adherence to infection control strategies may have contributed to the high incidence of seroconversion in this study. The general population prevalence of anti-HCV in Cameroon is 12.8%, [36] and the prevalence of anti-HCV antibodies among patients undergoing hemodialysis in Cameroon was 48% in 2003 using a third generation ELISA test [46]. The increased risk of seroconversion in facilities with a high prevalence of HCV has been reported by several authors [5,7,19-21] While some authors have advocated isolation of anti-HCV positive patients in facilities with a high prevalence [12,15,24,26]; current guidelines do not recommend any isolation policy. [47,26] Dedicating material and geographical space for some patients in a resource-limited setting is a difficult puzzle to solve.

The study setting was very conducive for the non-respect of recommendations for infection control. The use of multi-dose heparin vials [8], the high number of dialysis shifts per day, [22,29] understaffing [21,30] and a high proportion of inexperienced staff, [5] as seen in this study have been shown to promote non-adherence to infection control measures. Arenas et al found a patient-to-nurse ratio of 3 and above to be an independent factor affecting hand washing before and after an activity; while a high number of dialysis shifts per day was associated with lower rates of glove use and fewer glove changes between patients in hemodialysis [22]. Several studies have shown a spectacular decline in seroconversion rates with implementation of standard

precautions of infection control in HD.[18,35] A multicentric Belgian study reported a decline in incidence rate from 1.41% to 0% over a 54 months period through the implementation of universal precautions alone [18].

Some limits of this study must be mentioned. Firstly, the use of anti-HCV screening can overestimate HCV infection in the HD population [31, 39, 47, 48]. HCV RNA was only found in the sera of 84.1% of anti-HCV positive patients in one study. [39] However, cases of occult HCV infection where HCV RNA is negative in serum but positive in mononuclear cells have been described. [49] The additional use of optical density ratios as was done in this study highly increases the specificity of the third generation ELISA.[41]. False negative anti-HCV antibodies have also been described in a negligible proportion with third generation ELISA tests, [31,39,48] so the seroconversion rate in the present study is representative.

In conclusion, the rate of seroconversion to anti-HCV positivity is very high in this study. A longer duration on hemodialysis was found to be associated with seroconversion. Blood transfusion could not be shown to be an independent risk factor because of the small numbers. Although not directly evaluated, it is plausible that non-adherence to universal precautions and the high facility prevalence of HCV are the main contributors to this nosocomial infection.

This study provides a clue for preventive strategies for HCV in this population. A reduction in staff work- load and patient overcrowding as well as an audit of staff knowledge and adherence to infection control recommendations is necessary. The role of blood transfusion in seroconversion to HCV positivity in this setting needs further evaluation in more powered studies.

ACKNOWLEDGMENT

This study was partly funded by *Centre Pasteur du Cameroun*.

REFERENCES

- [1] Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Hepatitis C virus and death risk in hemodialysis patients. *J. Am Soc; Nephrol* 2007; 18:1584-1593
- [2] Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody- positive patients on regular hemodialysis therapy. *J. Am. Soc. Nephrol* 2000; 11: 1896-1902
- [3] Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ bank hepatitis C study group. *Kidney Int* 1998; 53:1374-1381

- [4] Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. *Am J Kidney Dis* 1998; 32: 629-634
- [5] Fissell R, Bragg-Gresham J, Woods J, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS *Kidney Int* 2004; 65:2335- 2342
- [6] Jadoul M, Poignet JL, Geddes C, et al. The changing epidemiology of hepatitis C virus (HCV) infection in hemodialysis: European multicenter study. *Nephrol. Dial. Transplant* 2004; 19(4): 904-909
- [7] Seyed-Moayed Alavian. A shield against a monster: Hepatitis C in hemodialysis Patients. *World J.Gastroenterol* 2009; 15(6): 641-646
- [8] Jadoul M. Epidemiology and mechanisms of transmission of the hepatitis C virus in hemodialysis. *Nephrol Dial Transplant* 2000; 15 (suppl 8): 39-46
- [9] Ayed K, Gorgi Y, Ben Abdallah, et al. Hepatitis C virus infection in hemodialysis patients from Tunisia: national survey by serological and molecular methods. *Transplant Proc* 2003 ; 35: 2573-2575
- [10] Izopet J, Sandres-Saune K, Kamar N, et al. Incidence of HCV infection in French hemodialysis centers: a prospective study. *J Med Virol* 2005; 77: 70-76
- [11] Taskapen H, Oymak O, Dogukan A, Utas C. Patient to patient transmission of hepatitis C virus in hemodialysis units. *Clin Nephrol* 2001; 55: 477-481
- [12] Agarwal SK, Dash SC, Gupta S, Pandey RM. Hepatitis C virus infection in hemodialysis: the 'no isolation' policy should not be generalized. *Nephron Clin Pract* 2009; 111: c 133-c140
- [13] El-Amin H.H, Osman E M, Mekki MO, et al. Hepatitis C virus infection in hemodialysis patients in Sudan: Two centers' study. *Saudi J kidney Dis Transplant* 2007; 18(1): 101-106
- [14] Hmaied F Ben Mamou M, Saune-Sandres K, Rostaing L, et al. Hepatitis virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission. *J.Med. Virol* 2006; 78: 185-191
- [15] Chen Yuqiang, Wang Niansong, Sheng Xiaohua, et al. Hepatitis C virus infection in uremic patients on maintenance hemodialysis: A follow up study for 150 months. *Afr. J. Microbiol. Res* 2011; 5(22): 3677-3683
- [16] Salama G, Rostang L, Sandres K, Rostaing Izopet J. Hepatitis C virus infection in French hemodialysis units: A multicenter study. *J Med Virol* 2000; 61: 44-51
- [17] Hardy NM, Sandroni S, Danielson S, et al. Antibody to hepatitis C virus increases with time on hemodialysis. *Clin.Nephrol* 1992; 38:44-48
- [18] Jadoul M, Cornu C, Van Ypersele de Strihou C and the UCL Collaborative Group. Universal precautions prevent hepatitis C virus transmission: a 54 month follows up of the Belgian Multicenter Study. *Kidney Int* 1998 ; 53(4): 1022-1025
- [19] Pujol F.H., Ponce JG, Lema MG, et al. High incidence of hepatitis C virus infection in hemodialysis patients in units with high prevalence. *J. Clin Microbiol* 1996; 34:1663-1666
- [20] Hinrichsen H, Leimenstoll G, Stegen G, et al. Prevalence of and risk factors for hepatitis C infection in hemodialysis patients: A multicentre study in 2796 patients. *Gut* 2002; 51: 429-433
- [21] Petrosillo N, Gilli P, Serraino D, et al. Prevalence of infected patients and understaffing has a role in hepatitis C virus transmission in dialysis. *Am J Kidney Dis* 2001; 37: 1004-1010
- [22] Arenas MD, Sanchez-Paya J, Barril G, et al. A multicentric survey of the practice of hand hygiene in haemodialysis units: factors affecting compliance. *Nephrol Dial Transplant* 2003; 2:1164-1171,
- [23] Espinosa M, Martn-Malo A, Ojeda R, Santamara R, Soriano S. Marked reduction in the prevalence of hepatitis C virus

- infection in hemodialysis patients: causes and consequences. *Am J. Kidney. Dis* 2004; 43(4): 685-689
- [24] Barril G, Traver JA. Decrease in the hepatitis C virus (HCV) prevalence in hemodialysis patients in Spain: effect of time, initiating HCV prevalence studies and adoption of isolation measures. *Antiviral Res* 2003; 60: 129-134
- [25] S.K. Agarwal. Hemodialysis of Patients with HCV Infection: Isolation has a Definite Role. *Nephron Clin Pract* 2011; 117: c328-c332
- [26] Center for Disease Control and prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. *MMWR. Recomm. Rep* 2001; 50:1-43
- [27] Jadoul M, Cornu C, Van Ypersele de Strihou C and the UCL Collaborative Group. Incidence and risk factors for hepatitis C seroconversion in hemodialysis. A prospective study. *Kidney Int* 1993; 44:1322-1326
- [28] Jadoul M. Transmission routes of HCV infection in dialysis. *Nephrol Dial Transplant* 1996; 11 (suppl 4): S36-S38
- [29] Ginou E, Chevaliez S, Challine D et al Determinant role of environmental contamination and noncompliance to standard precautions in the risk of hepatitis C virus transmission in a Hemodialysis Unit. *Clin Infect Dis.* 2008; 47(5): 627-633
- [30] Saxena AK, Panhotra BR. The impact of nurse understaffing on the transmission of hepatitis C virus in a hospital -based hemodialysis Unit. *Med Princ Pract.* 2004; 13(3):129-135
- [31] Khan S, Attanllah S, Ali I, et al. Rising burden of Hepatitis C virus in hemodialysis. *Virology journal* 2011; 8: 438 Doi: 10.1186/1743-422X-8-438
- [32] Soliman A, Abd Elaziz M, El Lawindi M. Evaluation of an isolation program of Hepatitis C virus infected Hemodialysis patients in some hemodialysis centers in Egypt. *ISRN Nephrology Volume 2013 Article ID 395467, 5 pages.* doi.org/10.5402/2013/395467.
- [33] Caramelo C, de Sequera P, Lopez MD, Ortiz A. Hand borne mechanisms of dissemination of hepatitis C virus in dialysis units: basis for new addenda to the present preventive strategies. *Clin Nephrol* 1999; 51: 59-60
- [34] Alfurayh O, Sabeel A, Al Ahdal MN, et al. Hand contamination with hepatitis C virus in staff looking after hepatitis C-positive hemodialysis patients. *Am. J Nephrol* 2000; 20: 103-106, 2000.
- [35] Valtuille R, Moretto H, Lef L, Rendo P, Fernandez JL. Decline of high hepatitis C virus prevalence in a hemodialysis unit with no isolation measures during a 6-year follow up. *Clin Nephrol* 2002; 57: 371-375
- [36] Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. *Lancet Infect Dis* 2002; 2: 293-302
- [37] Mbanya D, Binam F, Kaptue L. Transfusion outcome in a resource limited setting in Cameroon: a five-year evaluation. *Int. J Infect Dis* 2001; 5(2): 70-73
- [38] Bello B.T, Raji Y.R, Sanusi I, Braimoh R.W, Amira O.C, Mabayoje O.M. Challenges of providing maintenance hemodialysis in a resource poor country-Experience from a single teaching hospital in Lagos, Southwest Nigeria. *Hemodialysis International* 2013; Feb.3 doi:10.1111/hdi.12024
- [39] El-Ottol A, Elmanama A, Ayesh B. Prevalence and risk factors of Hepatitis B and C viruses among hemodialysis patients in Gaza Strip, Palestine. *Virology Journal* 2010; 7:210
- [40] Saraladevi Naicker. The Burden of End-stage renal disease in sub-Saharan. *Nephrol* 2010; 74(suppl. 1): S13-S16
- [41] Njouom R, Pasquier C, Ayouba A, et al. Hepatitis C virus infection among pregnant women in Yaounde, Cameroon: Prevalence, viremia, and genotypes. *J Med Virol* 2003; 69(3):384-390
- [42] Khodir S, Alghateb M, Okasha K, El-Saed Shalaby S. Prevalence of HCV infections among Hemodialysis Patients in Al Gharbiyah Governate, Egypt. *Arab Journal of Nephrology and Transplantation* 2012; 5(3):145-147
- [43] Arenas MD, Sanchez-Paya J. Standard precautions in hemodialysis: the gap between theory and practice. *Nephrol Dial Transplant* 1999; 14: 823-825
- [44] Dussol B, Chicheporhche C, Cantaloube JF. Detection of Hepatitis C infection by Polymerase Chain Reaction among Hemodialysis patients. *Am J Kidney Dis* 1993; 22: 574-580
- [45] Donahue JG, Munoz A, Ness PM, et al. The declining risk of post-transfusional hepatitis C virus infection. *N Engl J Med* 1992; 327: 369-373
- [46] Diffo C. «Prévalence des hépatites B, C et co-infection avec le VIH chez les hémodialysés chronique de l'Hôpital General de Douala». MD thesis, Faculty of Medicine & Biomedical Sciences, University of Yaounde 1, 2003
- [47] Kidney Disease: Improving Global Outcomes. KDIGO Clinical Practice Guidelines for Prevention, diagnosis, evaluation and treatment of Hepatitis C in Chronic Kidney Disease. *Kidney Int* 2008; 73(Suppl. 109): S1-S99
- [48] Baccari M, Rizzolo L, Ottolenghi A, Sorgato G. Hepatitis C virus screening strategies in Hemodialysis Units. *Nephrol Dial Transplant* 2002; 17: 1536
- [49] Fabrizi F, Martin P. Occult Hepatitis C virus infection in Hemodialysis. *J Am Soc. Nephrol* 2010; 19: 2248-2250